Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bayer says to comply with court mediation order in glyphosate case

Published 12/04/2019, 11:08
Updated 12/04/2019, 11:10
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

FRANKFURT (Reuters) - Bayer (DE:BAYGN) said on Friday it would comply with a U.S. federal judge's order to enter mediation with a plaintiff who claims the company failed to warn against an alleged cancer risk from its Roundup weedkiller.

Bayer has seen billions wiped off its market value since August, when a first U.S. jury found Bayer liable because Monsanto (NYSE:MON), acquired by Bayer for $63 billion last year, had not warned of the alleged risk from Roundup, which is based on active ingredient glyphosate.

It suffered a similar courtroom defeat last month and more than 10,000 cases are pending.

U.S. District Judge Vince Chhabria, who presided over the first two cases in federal court, said in a filing dated Thursday that Bayer and another plaintiff, Elaine Stevick, were ordered to start confidential mediation.

"The parties should propose a mediator in their case management statement; if they cannot agree, the Court will appoint someone," the judge ordered, cancelling a previously scheduled May 20 trial date.

Bayer said on Friday it would comply with the order in good faith, while believing strongly in the "extensive body of reliable science supporting the safety of Roundup".

"As this litigation is still in the early stages — with only two verdicts and no cases that have run their course through appeal — we will also remain focussed on defending the safety of glyphosate-based herbicides in court," it said.

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.